Notice of convocation of the Annual General Shareholders Meeting and documents related to the Annual General Meeting

Current Report No. 15/2024

Date of preparation: May 29, 2024

Subject: Notice of convocation of the Annual General Shareholders Meeting and documents related to the Annual General Meeting

The Management Board of Captor Therapeutics S.A., based in Wrocław (the ‘Company’), pursuant to Article 395, Article 399 § 1 in connection with Articles 402¹ and 402² of the Commercial Companies Code, announces that it has convened an Annual General Meeting of the Company for 27 June 2024, at 2:00 p.m. The Annual General Meeting will be held in Wrocław in the DELTA building at 9 Duńska Street, 54-427 Wrocław.

The Management Board of the Company provides in the attachment to this report:

1. the full text of the announcement with the agenda of the Annual General Meeting (attachment no. 1);

2. draft resolutions to be discussed at the Annual General Meeting of the Company (attachment  no. 2);

3. the content of the resolution of the Supervisory Board giving a positive opinion on the draft resolutions to be discussed at the Annual General Meeting of the Company (attachment  no. 3);

4. the opinion of the Company's Management Board on the amendment of the authorisation of the Company's Management Board to increase the Company's share capital within the limits of the authorised capital with the option to exclude in full the pre-emptive rights of existing shareholders and to amend the Company's Articles of Association in connection with the Company's authorised capital - amendment to Resolution No. 25 of the Annual General Meeting of 26 June 2020, as further amended, on the authorisation of the Company's Management Board to increase the Company's share capital within the limits of the authorised capital with the option to exclude the pre-emptive rights of existing shareholders and to amend the Company's Articles of Association in connection with the Company's authorised capital (attachment no.  4);

5. the remuneration report prepared by the Supervisory Board of the Company for the year 2023 (attachment 5);

6. the independent auditor's report on the performance of an attestation service providing reasonable assurance on the assessment of the remuneration report of Captor Therapeutics S.A. for the year 2023 (attachment no. 6);

7. the report of the Supervisory Board of the Company for the year 2023 (attachment  no. 7).

8. specimen power of attorney (attachment  no. 8).

9. specimen instruction to exercise voting rights by proxy (attachment  no. 9).

10. information on the total number of votes (attachment no. 10).